Thumbnail Image
Publication

A phase II study of selective AXL inhibitor bemcentinib and pembrolizumab in patients with NSCLC refractory to anti-PD(L)1

Krebs, Matthew G
; 
Brunsvig, P
; 
Helland, A
; 
Vinolas, N
; 
Aix, S
; 
Carcereny, E
; 
Gomez, MD
; 
Perez, JMT
; 
Arriola, E
; 
Campelo, RG
... show 10 more
Citations
Altmetric:
Abstract
Authors
Krebs, Matthew G
Brunsvig, P
Helland, A
Vinolas, N
Aix, S
Carcereny, E
Gomez, MD
Perez, JMT
Arriola, E
Campelo, RG
Spicer, J
Thompson, J
Granados, ALO
Holt, R
Smethurst, D
Lorens, J
Shoaib, M
Siddiqui, A
Schoelermann, J
Lorens, K
Schmidt, E
Chisamore, MJ
Felip, E
Affiliation
Manchester Academic Health Sciences Centre, The Christie NHS Foundation Trust and the University of Manchester, Manchester
Description
Date
2019
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Krebs M, Brunsvig P, Helland Å, Viñolas N, Aix S, Carcereny E, et al. P1.01-72 A Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1. Journal of Thoracic Oncology. 2019;14(10):S388.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/622535
Embedded videos